Physician profile
Ihab Dana
NPI 1124009410
$1,959.49
in general payments reported to CMS, 2019-2025
23 companies · $674 in 2025
The $674 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $66.99 · 2021: $128 · 2022: $193 · 2023: $258 · 2024: $453 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,385.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $531.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $281.06 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $144.13 | 2022-2025 | |
| Abbott Laboratories | $142.45 | 2022-2025 | Freestyle Libre 3 |
| Boston Scientific Corporation | $118.91 | 2023-2024 | Accolade Sr |
| Lilly USA, LLC | $103.68 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $89.61 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $68.25 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $66.18 | 2025 | Camzyos |
| Glaxosmithkline, LLC. | $56.75 | 2019-2023 | Arexvy |
| Astrazeneca Pharmaceuticals LP | $45.94 | 2019-2022 | |
| Mylan Specialty L.P. | $44.67 | 2019-2023 | Yupelri |
| Vapotherm INC | $36.98 | 2021 | |
| Amgen INC. | $36.26 | 2022-2025 | Repatha, Otezla |
| Dexcom, INC. | $33.63 | 2025 | Dexcom G6 Transmitter |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $31.16 | 2024 | |
| Xeris Pharmaceuticals, INC. | $21.93 | 2023 | Keveyis |
| Allergan, INC. | $19.85 | 2019 | |
| Intercept Pharmaceuticals, INC. | $18.89 | 2020 | |
| Astellas Pharma US INC | $18.19 | 2025 | Veozah |
| Medtronic Vascular, INC. | $18.08 | 2019 | |
| Eisai INC. | $17.20 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ihab Dana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.